MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Pupil response is impaired in clinically isolated REM Sleep Behavior Disorder and Parkinsons’ Disease

    W. Hermann, M. Brandt, T. Sehr, U. Walter, H. Reichmann, A. Storch, T. Ziemssen (Rostock, Germany)

    Objective: Since easily accessible (bio-) markers are needed to predict progression and outcome in prodromal stages of neurodegenerative diseases this study was designed to evaluate…
  • 2023 International Congress

    Modifying clinical and electrophysiological parameters through Transcranial pulsed current stimulation (tPCS) in Huntington disease

    M. Tuesta Bernaola, J. Ganguly, A. Parra Peña, M. Jog (London, Canada)

    Objective: 1. To assess brain network dysfunction of Huntington disease (HD). 2. To evaluate the effectiveness of 2-week home-based chronic non-invasive transcranial brain stimulation to…
  • 2023 International Congress

    Alterations of the Right Olfactory Orbitofrontal Cortex and olfactory impairment in Parkinson’s Disease

    L. Pesantez Pacheco, M. Saquib, D. Ehrlich, M. Hallett, S. Horovitz (Bethesda, USA)

    Objective: To explore the potential role of the right olfactory orbitofrontal cortex in olfactory dysfunction (OD) in Parkinson’s Disease (PD). Background: The orbitofrontal cortex (OFC)…
  • 2023 International Congress

    Clinical toolkits to improve conversations about Parkinson’s dementia

    I. Dobreva, J. Thomas, M. Roche, C. Dore, S. Rose, S. Baldwin-Jones, R. O'Connell, A. Marr, C. Hugill, R. Weil (London, United Kingdom)

    Objective: To co-produce, with people living with Parkinson’s and professionals, a pair of toolkits to improve conversations about Parkinson’s dementia in the clinic: one for…
  • 2023 International Congress

    Thymoquinone and Edible Bird Nest: The Secret Ingredients to Protect Against MPTP-induced zebrafish Parkinson’s disease

    W. Mohamed (Kuantan, Malaysia)

    Objective: Objectives: to create and validate an MPTP neurotoxin-based zebrafish model of Parkinson's disease and explore the therapeutic potential and neuroprotective effects of thymoquinone and…
  • 2023 International Congress

    Prevalence of cardiovascular drugs and oral anticoagulants use among persons with and without Parkinson’s disease

    B. Babar (Kuopio, Finland)

    Objective: We investigated prevalence of Cardiovascular drugs and Oral anticoagulants (OAC) use among community-dwelling persons with and without Parkinson's disease (PD) in relation to PD…
  • 2023 International Congress

    Glycated alpha-synuclein and it emerging role in early onset of Parkinson’s disease

    S. Chatterjee, H. Thakkar, A. Khairnar, R. Shah (Gandhinagar, India)

    Objective: To elucidate, the molecular mechanism underlying glycated α-Syn mediated dopaminergic (DAergic) neurodegeneration in the substantia nigra (SN) via the AGE/RAGE signaling pathway. Background: Intracytoplasmic…
  • 2023 International Congress

    Parkinson’s disease (PD) progression is associated with past exposure to organic contaminants in water at Marine Corps Base Camp Lejeune

    S. Goldman, F. Weaver, B. Gonzalez, K. Stroupe, L. Cao, K. Colletta, E. Brown, C. Tanner (San Francisco, USA)

    Objective: To test whether PD progression is more rapid in individuals who were exposed to volatile organic compounds in the water supply at Camp Lejeune…
  • 2023 International Congress

    Age-associated changes in the striatal proteins in aging Asian-Indians

    H J. Jyothi, A. Mahadevan, T C. Yasha, P. Alladi (Bengaluru, India)

    Objective: To examine the age-related changes in tyrosine hydroxylase (TH), vesicular monoamine transporter2 (VMAT2), post-synaptic density protein-95 (PSD-95) and dopamine receptors (D1R, D2R) expression in the…
  • 2023 International Congress

    An evaluation of NBI-827104 for essential tremor: results from a randomized, double-blind, placebo-controlled, dose-escalation, crossover study

    C. de Cuba, L. Smits, P. Kremer, R-J. Doll, J. Heuberger, R. Helmich, A F. van Rootselaar, R. Elble, W. Ondo, L. Rees, N. Wedick, G. Liang, D. Haubenberger (Leiden, Netherlands)

    Objective: To evaluate the efficacy of NBI-827104 in patients with essential tremor (ET). Background: NBI-827104 is a T-type calcium channel blocker that demonstrated tremorolytic activity…
  • « Previous Page
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • 29
  • …
  • 186
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley